Benzinga · Aug 17, 2026
HC Wainwright & Co. Reiterates Buy on Kodiak Sciences, Maintains $58 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Kodiak Sciences (NASDAQ:KOD) with a Buy and maintains $58 price target.
KO
NASDAQ · KOD
Kodiak Sciences Inc.
Healthcare · Biotechnology
$39.12
Down-$0.21 (-0.53%)
Updated Aug 28, 2026, 9:54 AM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.28B
- P/E ratio
- -8.18
- Dividend yield
- 0.00%
- 52-week range
- $8.29 – $47.84
- Volume
- 475.42K
- Avg. volume
- 929.49K
Price performance
KOD price history
1M range · 21 trading sessions · Daily adjusted prices
KOD closed at $39.12 after 21 trading sessions, down 7.95% for the selected period.
- Last close
- $39.12
- Period change
- -7.95%
- Period low
- $37.22
- Period high
- $45.40
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $39.37 | $40.11 | $38.6496 | $39.12 | 475.42K |
| Aug 26, 2026 | $39.94 | $40.0275 | $38.40 | $39.33 | 296.81K |
| Aug 25, 2026 | $37.99 | $39.68 | $37.70 | $39.46 | 571.32K |
| Aug 24, 2026 | $38.33 | $38.90 | $36.46 | $37.22 | 717.5K |
| Aug 21, 2026 | $40.39 | $40.90 | $37.99 | $38.33 | 509.12K |
| Aug 20, 2026 | $39.50 | $40.515 | $38.69 | $39.84 | 486.65K |
| Aug 19, 2026 | $41.72 | $41.72 | $39.30 | $40.07 | 595.82K |
| Aug 18, 2026 | $40.06 | $40.94 | $39.06 | $40.65 | 623.78K |
| Aug 17, 2026 | $40.57 | $43.04 | $39.87 | $40.98 | 628.34K |
| Aug 14, 2026 | $37.40 | $42.00 | $36.35 | $41.35 | 747.15K |
| Aug 13, 2026 | $43.82 | $44.50 | $39.15 | $39.98 | 815.01K |
| Aug 12, 2026 | $43.34 | $43.64 | $42.22 | $43.41 | 382.97K |
| Aug 11, 2026 | $43.47 | $43.80 | $41.21 | $42.11 | 515.92K |
| Aug 10, 2026 | $44.86 | $46.09 | $42.765 | $43.40 | 537.25K |
| Aug 7, 2026 | $46.12 | $46.87 | $45.105 | $45.37 | 511.44K |
| Aug 6, 2026 | $43.66 | $46.15 | $43.44 | $45.40 | 638.89K |
| Aug 5, 2026 | $43.00 | $44.25 | $42.33 | $43.61 | 525.29K |
| Aug 4, 2026 | $40.49 | $42.99 | $39.38 | $42.89 | 709.02K |
| Aug 3, 2026 | $41.67 | $41.88 | $39.40 | $39.83 | 578.67K |
| Jul 31, 2026 | $42.45 | $42.925 | $40.35 | $41.58 | 426.73K |
| Jul 30, 2026 | $40.92 | $42.73 | $40.52 | $42.50 | 628.87K |
Latest KOD news
The latest Smart Investors Daily articles mentioning KOD.
Stock researchCompany · Overview
KOD research
Overview
Company profile and research snapshot.
Company profile
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $17.00
- Implied upside
- —
- Analysts
- 12
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 3, 2026 | JP Morgan | Overweight | — |
| May 11, 2026 | Chardan Capital | Buy | — |
| Mar 27, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 27, 2026 | UBS | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 13, 2026
Kodiak Sciences Q2 EPS $(1.05) Misses $(0.95) Estimate
Kodiak Sciences (NASDAQ:KOD) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.95) by 10.53 percent. This is a 1.94 percent decrease over losses of $(1.03) per share from
Benzinga · Aug 10, 2026
Kodiak Sciences Enrols First Patients In Global Phase 3 ALTO Trial Evaluating KSI-501 In Patients With Diabetic Macular Edema
Phase 3 ALTO trial designed to demonstrate superiority of KSI-501 versus aflibercept in patients with diabetic macular edemaPALO ALTO, Calif., Aug. 10, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a
Benzinga · Aug 3, 2026
JP Morgan Maintains Overweight on Kodiak Sciences, Raises Price Target to $66
JP Morgan analyst Anupam Rama maintains Kodiak Sciences (NASDAQ:KOD) with a Overweight and raises the price target from $56 to $66.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
